LivaNova PLC (NASDAQ:LIVN - Get Free Report) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $48.71 and traded as low as $47.60. LivaNova shares last traded at $47.82, with a volume of 562,307 shares.
Analysts Set New Price Targets
Several research analysts recently commented on LIVN shares. Mizuho dropped their target price on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, October 31st. Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a research note on Tuesday, January 28th. StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, January 23rd. Finally, Robert W. Baird raised their target price on LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, LivaNova presently has a consensus rating of "Buy" and an average price target of $69.17.
View Our Latest Stock Report on LivaNova
LivaNova Trading Down 1.4 %
The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.60 billion, a price-to-earnings ratio of 113.88 and a beta of 1.00. The business has a 50-day moving average of $48.54 and a two-hundred day moving average of $49.67.
Insiders Place Their Bets
In related news, Director Francesco Bianchi sold 1,250 shares of the company's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now owns 7,522 shares of the company's stock, valued at $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.27% of the company's stock.
Institutional Investors Weigh In On LivaNova
Institutional investors have recently added to or reduced their stakes in the stock. Atria Investments Inc grew its position in LivaNova by 6.2% in the third quarter. Atria Investments Inc now owns 5,653 shares of the company's stock valued at $297,000 after purchasing an additional 331 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in shares of LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company's stock worth $328,000 after buying an additional 425 shares during the last quarter. Xponance Inc. grew its holdings in shares of LivaNova by 6.1% in the 4th quarter. Xponance Inc. now owns 7,762 shares of the company's stock valued at $359,000 after acquiring an additional 445 shares in the last quarter. Swiss National Bank increased its position in shares of LivaNova by 0.7% in the fourth quarter. Swiss National Bank now owns 106,819 shares of the company's stock valued at $4,947,000 after acquiring an additional 700 shares during the last quarter. Finally, Central Pacific Bank Trust Division raised its holdings in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock worth $191,000 after acquiring an additional 720 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
About LivaNova
(
Get Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Further Reading
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
